Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28441891 | 0.87 | NPC1 (0.38) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL16076085 | 0.85 | PTGS2 (0.39) | NPC1RAB9AALDH1A1HPGDPTGS2 | |
| SCHEMBL1700136 | 0.84 | PTGS2 (0.48) | ALDH1A1HPGDPTGS2SMN1; SMN2PTGS1 | |
| SCHEMBL30790602 | 0.84 | PTGS2 (0.48) | ALDH1A1LMNAPTGS2PTGS1 | |
| SCHEMBL16037816 | 0.80 | ESR2 (0.33) | NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL21430409 | 0.80 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL16038856 | 0.80 | PTGS1 (0.33) | PTGS2PTGS1 | |
| SCHEMBL21430678 | 0.79 | HTR2C (0.36) | ALDH1A1LMNABRD4SMN1; SMN2 | |
| SCHEMBL16037711 | 0.77 | SLC6A3 (0.47) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL30790565 | 0.75 | HSD17B10 (0.39) | ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2L11, BCL2, BCL2L2 | NPC1 2555/4885RAB9A 3440/4885ALDH1A1 2458/4885 |
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | BCL2L11, BCL2, BCL2L1 | NPC1 2268/4885RAB9A 3042/4885ALDH1A1 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.